Skip to content
God Of Sound – Lifestyle
Author:
Atossa Therapeutics Inc
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 8, 2026
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
May 6, 2026
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
May 4, 2026
←
Previous Page
1
2